BD OneFlow LST and B-CLPD T1 receive FDA 510(k) clearance: what K260215 actually covers

Summary

FDA cleared BD OneFlow LST and B-CLPD T1 for specified FACSLyric use as a qualitative diagnostic aid. K260215 does not establish an MRD indication.

The evidence

A clearance that answers a narrower question than the headline

A laboratory evaluating standardized immunophenotyping no longer has to rely solely on a catalogue claim for these two tubes. The FDA's K260215 determination, dated 20 October 2026, establishes substantial equivalence for BD OneFlow LST and BD OneFlow B-CLPD T1, together with described BD FACSLyric configurations and associated assay modules. Waters publicly announced the clearance on 10 November 2026. Those are different dates and milestones.

BD OneFlow LST: qualitative immunophenotyping of mature lymphocyte populations and assistance in identifying abnormal mature B-, T- and NK-cell lineages in patients with known or suspected lymphoid-lineage malignancy or neoplasm, when used with lineage-specific BD OneFlow reagents. Its twelve reported antigens are CD3, CD4, CD5, CD8, CD19, CD20, CD38, CD45, CD56, Igκ, Igλ and TCRγδ.

BD OneFlow B-CLPD T1: used with LST as an aid in diagnosing B-cell non-Hodgkin lymphoma including CLL. Its eight antigens are CD10, CD19, CD20, CD23, CD43, CD45, CD79b and CD200. The indicated specimens include peripheral blood collected in K2 or K3 EDTA or sodium or lithium heparin, bone marrow collected in K2 EDTA, and lymph-node specimens. Results are interpreted by a pathologist or equivalent professional alongside other clinical or laboratory findings.

The FDA summary documents BD FACSuite Clinical Application version 1.5 and the relevant modules and fluorescence compensation reagents. It reports that analytical and clinical tests met the submitted acceptance criteria, without publishing the manufacturer's headline numerical CLL sensitivity/specificity in its summary.

Interpretation and limitations

Where the evidence ends

510(k) clearance is not a blanket endorsement of all tests or instrument combinations. The FDA lists particular assay, application and instrument configurations. Its indications describe qualitative immunophenotyping and diagnostic aid—not measurable residual disease (MRD), an automated definitive diagnosis or equivalence to European IVDR status. The FDA lists the 8-, 10- and 12-color FACSLyric hardware configurations. Its IVD immunophenotyping indication specifies up to eight fluorescence detection channels and two light-scatter channels; the assay and software must be indicated for the instrument.

Waters states 96.3% sensitivity, 98.2% specificity for CLL identification and 95% fewer manual steps, citing internal studies in its 10 November announcement. These figures are manufacturer-reported. The FDA public summary gives qualitative performance conclusions, not the corresponding numerical sensitivity/specificity or workflow comparison denominators; therefore CFCM does not independently validate those headline values. Local verification, training and clinical interpretation remain essential.

Regulatory manufacturer: BD Biosciences/Becton, Dickinson and Company is the applicant and remains legal manufacturer during the transition to Waters. The Waters press release is commercial communication, not an FDA clearance letter.

What this means for laboratories

Why it matters for clinical flow cytometry

A mobile-readable CFCM guide to BD OneFlow LST and B-CLPD T1, their qualitative diagnostic scope and the FDA decision on October 20, 2026.
Original CFCM illustration based on FDA K260215 and the Waters announcement; the FDA-listed FACSLyric configurations and the indicated assay scope must be checked in the instructions for use.

Open the detailed CFCM assay diagram at full size.

Assay panels and timeline

BD OneFlow LST: survey tube for mature B-, T- and NK-cell lineages; 12 antigens: CD3, CD4, CD5, CD8, CD19, CD20, CD38, CD45, CD56, Igκ, Igλ and TCRγδ.

BD OneFlow B-CLPD T1: aid in B-cell non-Hodgkin lymphoma and CLL diagnosis when used with LST; 8 antigens: CD10, CD19, CD20, CD23, CD43, CD45, CD79b and CD200.

Timeline: FDA substantial-equivalence decision, 20 October 2026; Waters announcement, 10 November 2026; planned U.S. commercial availability, spring 2027. The assays are a qualitative diagnostic aid, not MRD validation. Restricted instrument and software configurations apply.

The practical advantage of a standardized tube is not that it eliminates professional judgment. It may reduce panel preparation variability and simplify adoption, but only where its intended use, sensitivity, gating templates and reflex strategy fit a laboratory's patients and existing workflow. Before implementation, check the exact FACSLyric optical/assay configuration and FACSuite version; specimen types and anticoagulants; compensation QC and reagent stability; analytical performance verification and concordance against the local diagnostic pathway; abnormal population reporting and reflex panels; operator training and pathologist sign-out.

Daily Learning Pill: distinguish three dates in regulatory news: the FDA decision (20 October), the CLIA listing (effective 3 November), and the company announcement (10 November). None of these alone is evidence that a laboratory has implemented or locally verified the assay.

Primary sources: FDA clearance letter, indications and 510(k) summary K260215; Waters announcement, 10 November 2026. Original CFCM editorial analysis; not a substitute for IFU or local validation.

Source Date

October 20, 2026

Event date

October 20, 2026

Commercial Regulatory Status

FDA 510(k) K260215, Class II: BD OneFlow LST and B-CLPD T1 for the indicated FACSLyric/FACSuite Clinical setup. BD remains legal manufacturer while Waters completes regulatory transfer. Preorders announced 10 November; U.S. general availability planned spring 2027. No separate MRD indication or new IVDR clearance inferred.

Primary source

Read the source →

An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.

Editor and independence disclosure →

CFCM WEEKLY · EVERY SUNDAY

The science behind the signal, in your inbox.

Get evidence-led clinical flow cytometry news, original conference posters, figures from published papers, practical learning pills, an advanced quiz and the story of one CD marker each week. Free. No spam.

Get CFCM Weekly →

Complete the form and confirm the email we send you. Unsubscribe any time. Privacy policy.